dienogest has been researched along with Adenomyosis in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 13 (52.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y; Ji, M; Jiao, X; Li, J; Li, Q; Wang, G; Yuan, M | 1 |
| Lu, J; Lu, P; Miao, J; Tang, J | 1 |
| Harada, M; Hirano, M; Hirota, Y; Koga, K; Osuga, Y; Uehara, M; Wada-Hiraike, O; Yamamoto, N | 1 |
| Chen, LH; Feng, M; Hsu, LT; Wu, HM | 1 |
| Chan, IS; Chang, YH; Chen, YJ; Hsu, TF; Shih, YC; Wang, PH | 1 |
| Kobayashi, H | 1 |
| Guo, W; Hu, S; Lin, Y; Shen, Y | 1 |
| Sasagawa, T; Takagi, H; Takakura, M | 1 |
| Akira, S; Matsushima, T; Takeshita, T; Yoneyama, K | 1 |
| Akinishi, M; Iwai, K; Kawaguchi, R; Kobayashi, H; Matsubara, S; Nagayasu, M; Niiro, E; Tanase, Y; Yamada, Y | 1 |
| Fukui, Y; Hashimoto, T; Hayashi, T; Hirota, Y; Ikemura, M; Inoue, S; Kawazu, M; Kiyono, T; Kojima, S; Mano, H; Muraoka, A; Oda, K; Osuga, Y; Osuka, S; Saito, T; Sakata, S; Taguchi, A; Takeuchi, K; Takeyama, R; Tanaka, T; Tanaka, Y; Terao, Y; Ueno, T; Yoshida, E | 1 |
| Li, C; Li, F; Li, L; Li, N; Li, T; Xue, J | 1 |
| Ainsworth, AJ; Cope, AG; Stewart, EA | 1 |
| Ali, MK; Hassanin, AI; Yousef, AM; Youssef, AA | 1 |
| Asano, R; Miyagi, E; Nagai, K; Nakamura, T; Ono, N; Sugo, Y | 1 |
| Hagino, A; Osuga, Y; Watanabe, M | 1 |
| Fujimoto-Okabe, H; Hagino, A; Osuga, Y | 1 |
| Fujii, T; Fukuda, S; Harada, M; Hirata, T; Hirota, Y; Izumi, G; Koga, K; Nakazawa, A; Neriishi, K; Osuga, Y; Wada-Hiraike, O; Yamamoto, N | 1 |
| Mizunuma, H; Ota, K; Shiraishi, S; Takahashi, T | 1 |
| Ziegler, C | 1 |
| Fujii, T; Harada, M; Hirata, T; Hirota, Y; Izumi, G; Koga, K; Nakazawa, A; Osuga, Y; Saito, A; Takamura, M | 1 |
| Kimura, F; Kishi, Y; Murakami, T; Shimizu, Y; Suginami, H; Takahashi, K; Yamanaka, A | 1 |
| Fawzy, M; Mesbah, Y | 1 |
| Fujii, T; Harada, M; Hirata, T; Hirota, Y; Koga, K; Makabe, T; Miyashita, M; Osuga, Y; Sue, F; Takeuchi, A | 1 |
| Chaya, J; Hayashi, K; Kato, N; Nishino, K; Yamamuro, O | 1 |
3 review(s) available for dienogest and Adenomyosis
| Article | Year |
|---|---|
Segmented in vitro fertilization and frozen embryo transfer in dienogest-treated patient with adenomyosis: A case report and lierature review.
Topics: Adenomyosis; Adult; Embryo Transfer; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Nandrolone; Pregnancy | 2022 |
Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments.
Topics: Adenomyosis; Female; Humans; Pain; Prospective Studies; Quality of Life; Retrospective Studies | 2023 |
Current and Future Medical Therapies for Adenomyosis.
Topics: Adenomyosis; Dysmenorrhea; Female; Hormone Antagonists; Humans; Levonorgestrel; Menorrhagia; Nandrolone; Pain Measurement; Quality of Life | 2020 |
3 trial(s) available for dienogest and Adenomyosis
| Article | Year |
|---|---|
Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
Topics: Adenomyosis; Female; Humans; Levonorgestrel; Nandrolone; Pain | 2023 |
Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Topics: Adenomyosis; Adult; Contraceptives, Oral, Combined; Egypt; Female; Humans; Nandrolone; Pain Measurement; Uterine Hemorrhage | 2021 |
Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
Topics: Adenomyosis; Adult; Double-Blind Method; Female; Humans; Japan; Menstruation Disturbances; Middle Aged; Nandrolone; Pain Measurement; Pelvic Pain; Placebos; Severity of Illness Index; Treatment Outcome; Young Adult | 2017 |
19 other study(ies) available for dienogest and Adenomyosis
| Article | Year |
|---|---|
A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Topics: Adenomyosis; Cohort Studies; Dysmenorrhea; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Nandrolone | 2022 |
Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Topics: Adenomyosis; Female; Gonadotropin-Releasing Hormone; Humans; Nandrolone; Retrospective Studies; Treatment Outcome | 2022 |
Prediction of the final menstrual period in women taking Dienogest using estradiol and follicle-stimulating hormone values: a case-control study.
Topics: Adenomyosis; Case-Control Studies; Dysmenorrhea; Endometriosis; Estradiol; Estrogens; Female; Follicle Stimulating Hormone; Follicle Stimulating Hormone, Human; Humans; Menstruation | 2022 |
Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study.
Topics: Adenomyosis; Female; Gonadotropin-Releasing Hormone; Humans; Retrospective Studies; Uterus | 2023 |
Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest.
Topics: Adenomyosis; Adult; Endometriosis; Female; Humans; Leiomyoma; Quality of Life; Retrospective Studies; Risk Factors; Uterine Hemorrhage | 2023 |
Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
Topics: Adenomyosis; Adult; Cohort Studies; Drug Administration Schedule; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Middle Aged; Nandrolone; Recurrence; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2020 |
Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Topics: Adenomyosis; Adult; Contraceptives, Oral, Hormonal; Female; Hemorrhage; Humans; Middle Aged; Nandrolone; Retrospective Studies; Risk Factors | 2019 |
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.
Topics: Adenomyosis; Adult; Cell Proliferation; DNA Mutational Analysis; Endometriosis; Endometrium; Female; High-Throughput Nucleotide Sequencing; Humans; Hysterectomy; Middle Aged; Mutation; Myometrium; Nandrolone; Proto-Oncogene Proteins p21(ras); Receptors, Progesterone; Treatment Outcome; Young Adult | 2019 |
Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
Topics: Adenomyosis; Administration, Oral; Adult; Female; Hormone Antagonists; Humans; Lewis Blood Group Antigens; Nandrolone; Quality of Life; Retrospective Studies; Treatment Outcome | 2020 |
Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Topics: Adenomyosis; Endometriosis; Female; Humans; Nandrolone; Retrospective Studies | 2021 |
Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
Topics: Adenomyosis; Adult; Female; Hormone Antagonists; Humans; Middle Aged; Nandrolone | 2017 |
Long-term dienogest administration in patients with symptomatic adenomyosis.
Topics: Adenomyosis; Adult; Female; Hormone Antagonists; Humans; Longitudinal Studies; Middle Aged; Nandrolone; Retrospective Studies | 2018 |
Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
Topics: Adenomyosis; Adult; Combined Modality Therapy; Dysmenorrhea; Endometrial Ablation Techniques; Female; Hormone Antagonists; Humans; Menorrhagia; Microwaves; Middle Aged; Nandrolone; Outcome Assessment, Health Care; Retrospective Studies | 2018 |
Excerpts From the World Medical Literature.
Topics: Adenomyosis; Double-Blind Method; Female; Humans; Nandrolone; Pain | 2018 |
Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
Topics: Adenomyosis; Adult; Female; Humans; Metrorrhagia; Middle Aged; Nandrolone; Pilot Projects; Progesterone Congeners; Treatment Outcome | 2014 |
Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells.
Topics: Adenomyosis; Adult; Apoptosis; Cell Proliferation; Cells, Cultured; Endometrium; Estradiol; Female; Humans; Middle Aged; Nandrolone; Progesterone; Stromal Cells | 2014 |
Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
Topics: Adenomyosis; Administration, Oral; Adult; Endometriosis; Female; Humans; Injections, Subcutaneous; Menorrhagia; Middle Aged; Nandrolone; Pelvic Pain; Premenopause; Prospective Studies; Treatment Outcome; Triptorelin Pamoate | 2015 |
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis.
Topics: Adenomyosis; Administration, Oral; Adult; Antineoplastic Agents, Hormonal; Apoptosis; Cell Proliferation; Combined Modality Therapy; Down-Regulation; Endometrium; Female; Humans; Immunohistochemistry; Middle Aged; Myometrium; Nandrolone; Nerve Fibers; Nerve Growth Factor; Neurogenesis; Progestins | 2016 |
Effective salvage of acute massive uterine bleeding using intrauterine balloon tamponade in a uterine adenomyosis patient on dienogest.
Topics: Adenomyosis; Adult; Antineoplastic Agents, Hormonal; Female; Humans; Nandrolone; Uterine Balloon Tamponade; Uterine Hemorrhage | 2013 |